Why did GlucoTrack's operating expenses surge in Q2 2024?

GlucoTrack's operating expenses for Q2 2024 are not available. However, we can infer that the company's focus on research and development, along with potential strategic initiatives, might have led to increased expenses during that period.

1. **Investment in Research and Development**: GlucoTrack's commitment to advancing its glucose monitoring technology could have resulted in higher R&D expenses. The company's successful completion of a preclinical study for its epidural glucose monitoring sensor suggests that they have been investing in developing their technology.
2. **Strategic Initiatives**: The reverse stock split that GlucoTrack announced in May 2024 might indicate an effort to consolidate shares and improve the stock's market value. Such corporate actions can sometimes be accompanied by increased expenses related to legal and advisory fees.
3. **Potential for Increased Capital Expenditures**: The company's announcement of a reverse stock split could also imply a need to raise additional capital to finance operations. This might lead to increased expenses related to financing activities, which could be reflected in the operating expenses category if certain conditions are not met.

In summary, GlucoTrack's operating expenses in Q2 2024 likely surged due to investments in research and development, potential strategic initiatives, and possibly increased capital expenditures.